4,7-二氯噌啉 | 82362-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4,7-二氯噌啉
• 英文名称: 4,7-dichloro-cinnoline
• 英文别名: 4,7-Dichlor-cinnolin；4,7-Dichlorocinnoline
• CAS: 82362-93-4
• 化学式: C₈H₄Cl₂N₂
• 分子量: 199.039
• InChiKey: NINQYOWDHNSQQS-UHFFFAOYSA-N

物化性质

• 熔点：
  143-143.5 °C
• 沸点：
  337.5±45.0 °C(Predicted)
• 密度：
  1.486±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  4,7-二氯噌啉 在 氢氧化钾 作用下， 生成 N,N-diethyl-N'-(7-chloro-cinnolin-4-yl)-ethylenediamine
  参考文献：
  名称：

  170.合成抗疟药。第XX部分。五线谱。第十三部分。4-氨基烷基氨基cinnolines的合成及抗疟作用

  摘要：

  DOI：

  10.1039/jr9470000917
• 作为产物：
  描述：

  1-(2-氨基-4-氯苯基)乙酮 在 盐酸 、 三氯氧磷 作用下， 生成 4,7-二氯噌啉
  参考文献：
  名称：

  五线谱; 氨基苯乙酮和氨基苯乙酮的合成。

  摘要：

  DOI：

  10.1021/jo01174a018

文献信息

• 4-(cinnolinylamino or quinazolinylamino)benzenesulphonamides and
  申请人：John Wyeth & Brother Limited

  公开号：US04640920A1

  公开（公告）日：1987-02-03

  Novel quinazoline and cinnoline derivatives having the formula ##STR1## (wherein one of A and B is CH and the other one of A and B is N; X.sub.1 is halogen or CF.sub.3 and X.sub.3 is one of the groups II, III, IV or V ##STR2## where Q is lower alkylene; R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are independently lower alkyl or R.sub.2 and R.sub.3 are a divalent radical such that HNR.sub.2 R.sub.3 is a secondary cyclic amine with 5 to 7 ring atoms; R.sub.4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I (where A, B and X.sub.1 are defined above and X.sub.3 is OH).

  具有以下结构式的新奎奈唑和咪唑衍生物（其中A和B中的一个是CH，另一个是N；X1是卤素或CF3，X3是II、III、IV或V中的一个基团，其中Q是较低的烷基烯；R1是氢或较低的烷基；R2和R3是独立的较低烷基，或者R2和R3是一种双价基团，使得HNR2R3是具有5至7个环原子的二级环胺；R4是较低的烷基；n为0或1；在III和IV式中显示的环是哌啶或吡咯啉，可以选择地被较低的烷基取代；在V式中显示的环是哌嗪，可以选择地被较低的烷基取代），以及它们的药学上可接受的盐在药物学中特别作为降压药物是有用的。还描述了新的中间体，包括式I的相应磺酸（其中A、B和X1如上所定义，X3是OH）。
• 4-substituted-N-(piperidinyl or pyrrolidinyl)alkyl benzenesulfonamides
  申请人：John Wyeth & Brother Limited

  公开号：US04734510A1

  公开（公告）日：1988-03-29

  Novel quinazoline and cinnoline derivatives having the formula ##STR1## (wherein one of A and B is CH and the other one of A and B is N; X.sub.1 is halogen or CF.sub.3 and X.sub.3 is one of the groups II, III, IV or V ##STR2## where Q is lower alkylene; R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are independently lower alkyl or R.sub.2 and R.sub.3 are a divalent radical such that HNR.sub.2 R.sub.3 is a secondary cyclic amine with 5 to 7 ring atoms; R.sub.4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I (where A, B and X.sub.1 are defined above and X.sub.3 is OH).

  具有以下式子的新型喹嗪和咪唑啉衍生物##STR1##（其中A和B中的一个是CH，另一个是N；X.sub.1是卤素或CF.sub.3，X.sub.3是II，III，IV或V组之一##STR2##其中Q是低碳链；R.sub.1是氢或低碳基；R.sub.2和R.sub.3独立地是低碳基或R.sub.2和R.sub.3是二价基团，使得HNR.sub.2 R.sub.3是具有5到7个环原子的次级环状胺；R.sub.4是低碳基；n为0或1；在式III和IV中显示的环是哌啶或吡咯啉，可以选择地被低碳基取代；在式V中显示的环是哌嗪，可以选择地被低碳基取代），以及它们的药物可接受盐，可用作药物，特别是作为抗高血压药物。还描述了新的中间体，包括式I的相应磺酸（其中A，B和X.sub.1如上定义，X.sub.3为OH）。
• 4-quinazolinylamino and 4-cinnolinylamino benzenesulphonic acids and
  申请人：John Wyeth & Brother Limited

  公开号：US04808715A1

  公开（公告）日：1989-02-28

  Novel quinazoline and cinnoline derivatives having the formula ##STR1## (wherein one of A and B is CH and the other one of A and B is N; X.sub.1 is halogen or CF.sub.3 and X.sub.3 is one of the groups II, III, IV or V ##STR2## where Q is lower alkylene; R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are independently lower alkyl or R.sub.2 and R.sub.3 are a divalent radical such that HNR.sub.2 R.sub.3 is a secondary cyclic amine with 5 to 7 ring atoms; R.sub.4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I ( (where A, B and X.sub.1 are defined above and X.sub.3 is OH).

  具有以下公式的新奎嗪和茚嗪衍生物的化合物适用于制药，特别是作为降压药物：##STR1##（其中A和B中的一个是CH，另一个是N；X.sub.1是卤素或CF.sub.3，X.sub.3是II，III，IV或V中的一个基团##STR2##其中Q是低烷基；R.sub.1是氢或低烷基；R.sub.2和R.sub.3是独立的低烷基，或者R.sub.2和R.sub.3是二价基团，使得HNR.sub.2 R.sub.3是具有5到7个环原子的二级环状胺；R.sub.4是低烷基；n为0或1；公式III和IV中显示的环是哌啶或吡咯啉，可选择地被低烷基取代；公式V中显示的环是哌嗪，可选择地被低烷基取代。其中药学上可接受的盐也适用于制药。还描述了新的中间体，包括公式I的相应磺酸（其中A，B和X.sub.1如上定义，X.sub.3为OH）。
• Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors
  申请人：Amgen Inc.

  公开号：US20130150339A1

  公开（公告）日：2013-06-13

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了式I的化合物或其药学上可接受的盐，它们是电压门控钠通道抑制剂，特别是Nav 1.7的抑制剂。这些化合物用于治疗可通过钠通道抑制治疗的疾病，如疼痛性疾病。同时提供了含有本发明化合物的药物组合物。
• 811. Cinnolines. Part XXXV. Studies of the chloro- and hydroxy-cinnolines
  作者：A. R. Osborn、K. Schofield

  DOI：10.1039/jr9560004207

  日期：——